Supernus Pharmaceuticals, Inc.

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.

ACADIA Pharmaceuticals Inc.ACAD · PharmaceuticalsSan Diego, United States

68% matchPublicAI 9/100 ▼Green 0/100 ▼

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical enterprise dedicated to the identification, progression, and commercialization of innovative therapeutic solutions. Its primary focus lies in addressing neurodegenerative conditions across key markets including India, the United States, Europe, and other international territories. The company's core activities revolve around the discovery and subsequent development of new chemical entities (NCEs) specifically targeting disorders of the central nervous system (CNS). Among its promising pipeline assets are SUVN-502, intended for Alzheimer's disease and associated neuropsychiatric manifestations; SUVN-G3031, a potent and selective inverse agonist of the histamine H3 receptor, aimed at sleep and cognitive impairments; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist designed to alleviate depressive disorders. Further advancing its portfolio, Suven is also working on SUVN-D4010, a potent, selective, orally bioavailable, and brain-penetrant partial agonist of the 5-HT4 receptor for cognitive dysfunctions; SUVN-I6107, addressing cognitive issues and schizophrenia; SUVN-M8036 for various psychiatric ailments; and SUVN-D1044, targeting gastrointestinal conditions. Established in 1989, the company is based in Hyderabad, India. It adopted its current name, Suven Life Sciences Limited, in 2003, having previously operated as Suven Pharmaceuticals Pvt. Ltd. Jasti Property and Equity Holdings Private Limited holds a controlling interest in Suven Life Sciences Limited, making it a subsidiary.

Sun Pharma Advanced Research Company Limited (SPARC), a biopharmaceutical firm established in Mumbai, India, in 2006 and operating as a subsidiary of Shanghvi Finance Private Limited, is globally committed to the discovery and advancement of innovative pharmaceutical products. The company's strategic focus involves developing novel chemical and biological entities, as well as improving existing formulations, with a key therapeutic emphasis on conditions within oncology, neurodegeneration, ophthalmology, and dermatology. SPARC currently commercializes Elepsia, a specialized levetiracetam formulation for managing epilepsy, and Xelpros, a latanoprost ophthalmic emulsion prescribed for the treatment of open-angle glaucoma or ocular hypertension. Its robust development pipeline showcases numerous candidates in various clinical trial stages: SDN-037, a difluprednate formulation in Phase 3 for addressing inflammation and pain linked to ocular surgery; PDP-716, also in Phase 3 for glaucoma; and phenobarbital sodium, targeting neonatal seizures. Additionally, the company is progressing Vodobatinib (SCO-088), which has concluded Part A of its Phase 1 study for resistant chronic myelogenous leukemia, and Vodobatinib (SCC-138), currently in Phase 2 for Parkinson's disease. Other pipeline assets include SCD-044, a Phase 2 candidate for psoriasis and atopic dermatitis, and SCO-120, advancing through Phase 1 for hormone receptor-positive, HER2-negative, metastatic breast cancer. Complementing its internal efforts, SPARC engages in strategic collaborations, including one with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders, and another with HitGen Ltd. aimed at identifying promising small molecule leads for selected therapeutic targets.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.

LundbeckPharmaceuticalsDenmark

66% match

Lundbeck is a global pharmaceutical company headquartered in Copenhagen, Denmark, specializing in brain diseases. The company is committed to researching, developing, and delivering transformative therapies for these conditions, with additional US headquarters in Deerfield, Illinois.